Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy: A subset analysis from a randomized clinical phase III trial

Journal of Thoracic Oncology

Volumn 9, Issue 6, 2014, Pages 825-833

  Strøm, Hans H ^a,b   Bremnes, Roy M ^b,c   Sundstrøm, Stein H ^d   Helbekkmo, Nina ^c   Aasebø, Ulf ^b,c  

^a Helgeland Hospital   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Bulky tumors; Chemoradiotherapy; Locally advanced; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; NAVELBINE; ANTINEOPLASTIC AGENT; VINBLASTINE;

ADVANCED CANCER; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CHEMORADIOTHERAPY; CONTROLLED STUDY; ESOPHAGITIS; FEMALE; HUMAN; INOPERABLE CANCER; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR VOLUME; AGED; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; HOSPITALIZATION; LUNG NEOPLASMS; PALLIATIVE THERAPY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; SURVIVAL RATE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; DOSE FRACTIONATION; ESOPHAGITIS; FEMALE; HOSPITALIZATION; HUMANS; LUNG NEOPLASMS; MALE; PALLIATIVE CARE; PROGNOSIS; QUALITY OF LIFE; SURVIVAL RATE; TUMOR BURDEN; VINBLASTINE;

EID: 84901634898     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000184     Document Type: Article

References (41)

1. Cancer Registry N. Cancer in Norway 2009. Cancer Registry of Norway, 2011, Pp. 1-169.
2. Rolke HB, Bakke PS, Gallefoss F. Delays in the diagnostic pathways for primary pulmonary carcinoma in Southern Norway. Respir Med 2007: 1251-1251. (Pubitemid 46667667)
3. Lester JF, Macbeth FR, Toy E, Coles B. Palliative radiotherapy regimens for non-small cell lung cancer. Cochrane Database Syst Rev 2006;(4):CD002143.
4. Morgensztern D, Waqar S, Subramanian J, Gao F, Trinkaus K, Govindan R. Prognostic significance of tumor size in patients with stage III nonsmall- cell lung cancer: a surveillance, epidemiology, and end results (SEER) survey from 1998 to 2003. J Thorac Oncol 2012;7:1479-1484.
5. Alexander BM, Othus M, Caglar HB, Allen AM. Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 2011;79:1381-1387.
6. Wiersma TG, Dahele M, Verbakel WF, et al. Concurrent chemoradiotherapy for large-volume locally-advanced non-small cell lung cancer. Lung Cancer 2013;80:62-67.
7. Basaki K, Abe Y, Aoki M, Kondo H, Hatayama Y, Nakaji S. Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume. Int J Radiat Oncol Biol Phys 2006;64:449-454. (Pubitemid 43083431)
8. De Petris L, Lax I, Sirzén F, Friesland S. Role of gross tumor volume on outcome and of dose parameters on toxicity of patients undergoing chemoradiotherapy for locally advanced non-small cell lung cancer. Med Oncol 2005;22:375-381. (Pubitemid 43780294)
9. Bradley JD, Ieumwananonthachai N, Purdy JA, et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2002;52:49-57. (Pubitemid 34041565)
10. Ball D, Mitchell A, Giroux D, Rami-Porta R; IASLC Staging Committee and Participating Institutions. Effect of tumor size on prognosis in patients treated with radical radiotherapy or chemoradiotherapy for nonsmall cell lung cancer. An analysis of the staging project database of the International Association for the Study of Lung Cancer. J Thorac Oncol 2013;8:315-321.
11. O'Rourke N, Roqué I Figuls M, Farré Bernadó N, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2010;(6):CD002140.
12. Uitterhoeve ALJ, Koolen MGJ, van Os RM, et al. Accelerated high-dose radiotherapy alone or combined with either concomitant or sequential chemotherapy; treatments of choice in patients with non-small cell lung cancer. Radiat Oncol 2007;2:27.
13. Belderbos J, Uitterhoeve L, van Zandwijk N, et al; EORTC LCG and RT Group. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 2007;43:114-121. (Pubitemid 46054477)
14. Bradley JD, Hope A, El Naqa I, et al; RTOG. A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data. Int J Radiat Oncol Biol Phys 2007;69:985-992. (Pubitemid 47625854)
15. Strøm HH, Bremnes RM, Sundstrøm SH, Helbekkmo N, Fløtten O, Aasebø U. Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group. Br J Cancer 2013;109:1467-1475.
16. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment, 1979. Pp. 1.
17. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-1756. (Pubitemid 19272848)
18. Claassens L, van Meerbeeck J, Coens C, et al. Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials. J Clin Oncol 2011;29:2104-2120.
19. Groome PA, Bolejack V, Crowley JJ, et al; IASLC International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:694-705. (Pubitemid 47357521)
20. Fayers P, Bottomley A; EORTC Quality of Life Group; Quality of Life Unit. Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur J Cancer 2002;38(Suppl 4):S125-S133. (Pubitemid 34169774)
21. Fayers P, Aaronson N, Bjordal K, et al. EORTC QLQ-C30 Scoring Manual, 3rd Ed. Brussels, Belgium: European Organisation for Research and Treatment of Cancer, 2001.
22. Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J; Quality of Life Committee of the NCIC CTG. Analysis and interpretation of healthrelated quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2005;41:280-287. (Pubitemid 40126961)
23. Brundage M, Osoba D, Bezjak A, Tu D, Palmer M, Pater J; National Cancer Institute of Canada Clinical Trials Group. Lessons learned in the assessment of health-related quality of life: selected examples from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:5078-5081. (Pubitemid 350232286)
24. Crinò L, Weder W, van Meerbeeck J, Felip E; ESMO Guidelines Working Group. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v103-v115.
25. Moore R, Doherty D, Chamberlain R. Sex differences in survival in nonsmall cell lung cancer patients 1974-1998. Acta Oncol 2004;43:57-64. (Pubitemid 38283174)
26. Cerfolio RJ, Bryant AS, Scott E, et al. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest 2006;130:1796-1802. (Pubitemid 46033436)
27. Visbal AL, Williams BA, Nichols FC, et al. Gender differences in nonsmall- cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg 2004;78:209-215. (Pubitemid 38842439)
28. Jeremié B, Miličié B, Milisavljevic S. Clinical prognostic factors in patients with locally advanced (stage III) nonsmall cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy: single-Institution Experience in 600 Patients. Cancer 2011;117:2995-3003.
29. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002;122:1037-1057.
30. Buccheri G, Ferrigno D. Importance of weight loss definition in the prognostic evaluation of non-small-cell lung cancer. Lung Cancer 2001;34:433-440. (Pubitemid 33041479)
31. Werner-Wasik M, Paulus R, Curran WJ Jr, Byhardt R. Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: analysis of the radiation therapy oncology group (RTOG) database. Clin Lung Cancer 2011;12:245-251.
32. Phernambucq ECJ, Spoelstra FOB, Verbakel WFAR, et al. Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity. Ann Oncol 2011;22:132-138.
33. Wang XS, Fairclough DL, Liao Z, et al. Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms. J Clin Oncol 2006;24:4485-4491. (Pubitemid 46630988)
34. Pijls-Johannesma M, Houben R, Boersma L, et al. High-dose radiotherapy or concurrent chemo-radiation in lung cancer patients only induces a temporary, reversible decline in QoL. Radiother Oncol 2009;91:443-448.
35. Ball D, Smith J, Wirth A, Mac Manus M. Failure of T stage to predict survival in patients with non-small-cell lung cancer treated by radiotherapy with or without concomitant chemotherapy. Int J Radiat Oncol Biol Phys 2002;54:1007-1013. (Pubitemid 35292611)
36. Dehing-Oberije C, De Ruysscher D, van der Weide H, et al. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-smallcell lung cancer patients treated with (chemo)radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:1039-1044. (Pubitemid 351308062)
37. Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 2008;44:946-953.
38. Italiano A. Prognostic or predictive? It's time to get back to definitions! J Clin Oncol 2011;29:4718; author reply 4718-4718; author reply 4719
39. Werner-Wasik M, Swann RS, Bradley J, et al. Increasing tumor volume is predictive of poor overall and progression-free survival: secondary analysis of the Radiation Therapy Oncology Group 93-11 phase I-II radiation dose-escalation study in patients with inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008;70:385-390.
40. Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2181-2190.
41. Zhao L, West BT, Hayman JA, Lyons S, Cease K, Kong FM. High radiation dose may reduce the negative effect of large gross tumor volume in patients with medically inoperable early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2007;68:103-110. (Pubitemid 46589842)